Pharmaceuticals company Emcure Pharmaceuticals announced Q2FY26 results Revenue from operations at Rs 2,270 crore, up 13.4% YoY. EBITDA margins at 19.3% with EBITDA at Rs 439 crore up 15.2% YoY. PAT at Rs 251 crore, up 24.7% YoY. Domestic business sales at Rs 1,031 crore, up 10.6% YoY. International business sales at Rs 1,238 crore, up 15.8% YoY. Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals, said: “Q2 saw strong performance across all our businesses. We continue to augment our portfolio in all our focus markets though in-licensing and inhouse developments. Novo Nordisk partnership positions us well in the fast-growing obesity segment and gives us an early entry enabling us to shape the market. We remained focus on delivering strong growth along with margin improvement in all our key businesses.” Result PDF